<DOC>
	<DOCNO>NCT00699322</DOCNO>
	<brief_summary>This research focus effect Sitagliptin 24 hour glycemic excursion improvement oxidative stress marker compare long act sulphonylurea Glimepiride type 2 diabetic patient inadequate glycemic control metformin</brief_summary>
	<brief_title>Effect Dipeptidyl Peptidase-IV Inhibitor Sulfonylurea Glucose Variability Oxidative Stress</brief_title>
	<detailed_description>Sitagliptin might improve mean glycemic control study period also 24 hour glycemic fluctuation restore physiologic pattern insulin secretion . Furthermore decrease postprandial glycemic excursion decrease oxidative stress marker . Those effect might amplify Asian patient prominent early phase insulin secretory defect accompany relatively less degree insulin resistance . Based assumption , research focus effect Sitagliptin 24 hour glycemic excursion improvement oxidative stress marker compare long act sulphonylurea Glimepiride type 2 diabetic patient inadequate glycemic control metformin .</detailed_description>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<criteria>patient type 2 diabetes duration diabetes less 10 year HbA1c 6.58.0 % BMI 2030 stable dose metformin ( 1000mg ) least 2 month oral hypoglycemic agent metformin use insulin serum creatinin &gt; = 1.5 mg/dL SGOT , SGPT &gt; = 90 ischemic heart disease congestive heart failure ( NYHA class &gt; =2 ) severe diabetic complication ( PDR , CRF , CVA ) medication affect glucose profile ( steroid ) infectious disease malignancy pregnant breastfeeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>glucose variability</keyword>
	<keyword>oxidative stress</keyword>
	<keyword>sitagliptin</keyword>
	<keyword>glimepiride</keyword>
</DOC>